Breathe Well Live Well
|
MedImmune to present Phase IIb asthma data on benralizumab and …
News-Medical.net In the Phase IIb data being presented, both benralizumab and tralokinumab show promising safety and efficacy outcomes, suggesting they may offer important new therapeutic options for patients with specific forms of severe, uncontrolled asthma. |
View full post on asthma – Google News
 Telegraph.co.uk |
MedImmune parent, Amgen launch partnership
Gazette.Net: Maryland Community News Online AstraZeneca is to lead the development and commercial strategy of three candidates, AMG 139, AMG 157 and AMG 181, which are being studied to treat Crohn's disease, asthma and ulcerative colitis, respectively. Amgen will spearhead efforts regarding … Amgen and AstraZeneca Announce Collaboration to Jointly Develop and … Big Pharma Buys Access To This Promising Biotech Pipeline AstraZeneca, Amgen enter into development and commercialization agreement |
View full post on asthma – Google News
 Telegraph.co.uk |
AstraZeneca's MedImmune signs French research deal
Telegraph.co.uk Under the deal, they will initially work on 10 projects, with asthma among the first areas they will focus on. Photo: Newscast By Rachel Cooper 6:30AM BST 04 Apr 2011 MedImmune, the drug maker's biologics unit, has struck a three-year agreement with … |
View full post on asthma – Google News